XENE Jan 2025 42.500 call
| Previous close | 8.99 |
| Open | N/A |
| Bid | 4.10 |
| Ask | 5.90 |
| Strike | 42.50 |
| Expiry date | 2025-01-17 |
| Day's range | 8.99 - 8.99 |
| Contract range | N/A |
| Volume | |
| Open interest | 93 |
ZacksIntra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
GuruFocus.comXenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
Xenon Pharmaceuticals Inc (XENE) showcases robust financial health and promising developments in epilepsy and depression treatments.
GlobeNewswireXenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024. Fireside Chat Presentation Details: Date:Monday, October 7, 2024 Time:11:40 am Eastern Time Webc
